Vertically integrated Indian pharma manufacturer of APIs, intermediates and finished dosage formulations, and a global-scale producer of Chlorhexidine base and Ascorbic Acid
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 14 | 14 | 14 | 14 | 14 | 16 | 16 | 17 |
| Reserves | 164 | 245 | 315 | 354 | 265 | 450 | 471 | 516 |
| Borrowings | 91 | 181 | 257 | 415 | 333 | 223 | 238 | 249 |
| Other Liabilities | 74 | 86 | 136 | 115 | 154 | 144 | 114 | 141 |
| Total Liabilities | 343 | 526 | 721 | 898 | 765 | 833 | 839 | 923 |
| AssetsFixed Assets | 162 | 208 | 270 | 366 | 253 | 238 | 251 | 248 |
| CWIP | 5 | 57 | 52 | 22 | 7 | 3 | 6 | 8 |
| Investments | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 170 | 260 | 399 | 510 | 506 | 591 | 582 | 667 |
| Total Assets | 343 | 526 | 721 | 898 | 765 | 833 | 839 | 923 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 25 | 21 | 44 | 1 | -22 | 92 | 22 | 58 |
| Cash from Investing | -13 | -28 | -109 | -75 | -93 | -11 | -15 | -48 |
| Cash from Financing | -13 | 3 | 75 | 62 | 131 | -97 | -6 | 24 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 11 | -2 | -70 | -74 | -115 | 73 | 10 | 18 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
BAJAJHCARE · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.